Non-GCB DLBCL often carries alterations in genes related to the B-cell receptor (BCR) signaling pathway, such as MYD88 and CD79B.10 Bruton’s tyrosine kinase (BTK) is a key mediator of the BCR signaling pathway and is considered as a potential therapeutic target of non-GCB DLBCL. Here, BCR is linked to diffuse large B-cell lymphoma.